# Hospira, Inc., a Pfizer Company: Carboplatin Injection shortage update (unavailable from this maker)

**Score:** 70/100

| Field | Value |
|---|---|
| Manufacturer | Hospira, Inc., a Pfizer Company |
| Drug | Carboplatin Injection |
| Dosage form | Injection |
| Therapeutic category | Oncology |
| Status | Current |
| Stage | Shortage revised (availability or dates changed) |
| Availability | Unavailable |
| Reason | Other |
| Presentations affected | 8 |
| Package NDCs | 61703-262-05, 61703-339-50, 61703-339-56, 61703-360-18, 61703-339-18, 61703-150-05, 61703-339-22, 61703-600-05 |
| Manufacturer supply note | Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay |
| First posted | 2023-04-28 |
| Updated | 2026-10-21 |

## Why this score
- Shortage details just changed.
- Unavailable from this manufacturer.
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.